Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28639592
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Indian+J+Med+Res
2017 ; 145
(2
): 167-178
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Current status of lupus nephritis
#MMPMID28639592
Jaryal A
; Vikrant S
Indian J Med Res
2017[Feb]; 145
(2
): 167-178
PMID28639592
show ga
Systemic lupus erythematosus (SLE) is a systemic disease of unknown aetiology
with variable course and prognosis. Lupus nephritis (LN) is one of the important
disease manifestations of SLE with considerable influence on patient outcomes.
Immunosuppression therapy has made it possible to control the disease with
improved life expectancy and quality of life. In the last few decades, various
studies across the globe have clarified the role, dose and duration of
immunosuppression currently in use and also provided evidence for new agents such
as mycophenolate mofetil, calcineurin inhibitors and rituximab. However, there is
still a need to develop new and specific therapy with less adverse effects. In
this review, the current evidence of the treatment of LN and its evolution, and
new classification criteria for SLE have been discussed. Also, rationale for
low-dose intravenous cyclophosphamide as induction agent followed by azathioprine
as maintenance agent has been provided with emphasis on individualized and
holistic approach.
free
free
free
